• Molecular NameSolifenacin
  • Synonymsolifenacin succinate
  • Weight362.473
  • Drugbank_IDDB01591
  • ACS_NO242478-38-2
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.24
  • pkaN/A
  • LogD (pH=7, predicted)2.04
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.29
  • LogSw (predicted, AB/LogsW2.0)0.04
  • Sw (mg/ml) (predicted, ACD/Labs)0.03
  • No.of HBond Donors0
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds3
  • TPSA32.78
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with or without urge incontinence.
  • Absorption_valueN/A
  • Absorption (description)The absolute bioavailability of solifenacin is approximately 90%, and plasma concentrations of solifenacin are proportional to the dose administered.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding98.0
  • Volume of distribution (VD)8.6 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmSolifenacin is extensively metabolized in the liver. The primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist. The primary metabolic routes of solifenacin are through N-oxidation of the quinuclidin ring and 4R-hydroxylation of tetrahydroisoquinoline ring. One pharmacologically active metabolite (4R-hydroxy solifenacin), occurring at low concentrations and unlikely to contribute significantly to clinical activity, and three pharmacologically inactive metabolites (N-glucuronide and the N-oxide and 4R-hydroxy-N-oxide of solifenacin) have been found in human plasma after oral dosing.
  • Half life45~68 h
  • ExcretionRenal (69.2%) and fecal (22.5%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityOverdosage with solifenacin can potentially result in severe anticholinergic effects and should be treated accordingly. The highest solifenacin dose given to human volunteers was a single 100 mg dose. Intolerable anticholinergic side effects (fixed and dilated pupils, blurred vision, failure of heel-to-toe exam, tremors and dry skin) occurred on day 3 in normal volunteers taking 50 mg daily (5 times the maximum recommended therapeutic dose).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A